Johnson & Johnson
NYSE:JNJ

Watchlist Manager
Johnson & Johnson Logo
Johnson & Johnson
NYSE:JNJ
Watchlist
Price: 150.73 USD -1.08% Market Closed
Market Cap: 362.7B USD

EV/EBIT
Enterprise Value to EBIT

16
Current
16.5
Median
16.2
Industry
Lower than median
Lower than industry value

Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.

EV/EBIT
16
=
Enterprise Value
373.1B USD
/
EBIT
23.4B USD
Market Cap EV/EBIT
US
Johnson & Johnson
NYSE:JNJ
362.6B USD 16
US
Eli Lilly and Co
NYSE:LLY
744B USD 39.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 17 702.3
DK
Novo Nordisk A/S
CSE:NOVO B
2.1T DKK 16.2
CH
Roche Holding AG
SIX:ROG
206.1B CHF 10.9
CH
Novartis AG
SIX:NOVN
186.1B CHF 14
UK
AstraZeneca PLC
LSE:AZN
163.6B GBP 197.2
US
Merck & Co Inc
NYSE:MRK
199.5B USD 10.3
IE
Endo International PLC
LSE:0Y5F
163.5B USD 655.3
US
Pfizer Inc
NYSE:PFE
135.8B USD 10.4
FR
Sanofi SA
PAR:SAN
103.8B EUR 5.3
EBIT Growth EV/EBIT to Growth
US
Johnson & Johnson
NYSE:JNJ
Average EV/EBIT: 1 697.9
16
13%
1.2
US
Eli Lilly and Co
NYSE:LLY
39.3
32%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
DK
Novo Nordisk A/S
CSE:NOVO B
16.2
14%
1.2
CH
Roche Holding AG
SIX:ROG
10.9
6%
1.8
CH
Novartis AG
SIX:NOVN
14
10%
1.4
UK
AstraZeneca PLC
LSE:AZN
197.2
23%
8.6
US
Merck & Co Inc
NYSE:MRK
10.3
11%
0.9
IE
E
Endo International PLC
LSE:0Y5F
655.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.4
10%
1
FR
Sanofi SA
PAR:SAN
5.3
14%
0.4

EV/EBIT Forward Multiples

Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBIT
12.4
2-Years Forward
EV/EBIT
11.8
3-Years Forward
EV/EBIT
11.1

See Also

Summary
JNJ intrinsic value, competitors valuation, and company profile.
DCF Valuation
JNJ stock valuation using Discount Cash Flow valuation method.
Relative Valuation
JNJ stock valuation using valuation multiples.
Wall Street Estimates
JNJ price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
JNJ stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 262,600+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.